Sakurai T, Kojima C, Kobayashi Y, Hirano S, Sakurai M H, Waalkes M P, Himeno S
Laboratory of Molecular Nutrition and Toxicology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima, Japan.
Br J Pharmacol. 2006 Dec;149(7):888-97. doi: 10.1038/sj.bjp.0706899. Epub 2006 Oct 16.
Although inorganic arsenite (As(III)) is toxic in humans, it has recently emerged as an effective chemotherapeutic agent for acute promyelocytic leukemia (APL). In humans and most animals, As(III) is enzymatically methylated in the liver to weakly toxic dimethylarsinic acid (DMAs(V)) that is a major pentavalent methylarsenic metabolite. Recent reports have indicated that trivalent methylarsenicals are produced through methylation of As(III) and participate in arsenic poisoning. Trivalent methylarsenicals may be generated as arsenical-glutathione conjugates, such as dimethylarsinous glutathione (DMAs(III)G), during the methylation process. However, less information is available on the cytotoxicity of DMAs(III)G.
We synthesized and purified DMAs(III)G using high performance TLC (HPTLC) methods and measured its cytotoxicity in rat liver cell line (TRL 1215 cells).
DMAs(III)G was highly cytotoxic in TRL 1215 cells with a LC(50) of 160 nM. We also found that DMAs(III)G molecule itself was not transported efficiently into the cells and was not cytotoxic; however it readily became strongly cytotoxic by dissociating into trivalent dimethylarsenicals and glutathione (GSH). The addition of GSH in micromolar physiological concentrations prevented the breakdown of DMAs(III)G, and the DMAs(III)G-induced cytotoxicity. Physiological concentrations of normal human serum (HS), human serum albumin (HSA), and human red blood cells (HRBC) also reduced both the cytotoxicity and cellular arsenic uptake induced by exposure to DMAs(III)G.
These findings suggest that the significant cytotoxicity induced by DMAs(III)G may not be seen in healthy humans, even if DMAs(III)G is formed in the body from As(III).
尽管无机亚砷酸盐(As(III))对人类有毒,但它最近已成为治疗急性早幼粒细胞白血病(APL)的一种有效化疗药物。在人类和大多数动物中,As(III)在肝脏中被酶促甲基化,生成低毒的二甲基砷酸(DMAs(V)),它是主要的五价甲基砷代谢产物。最近的报告表明,三价甲基砷化合物是通过As(III)的甲基化产生的,并参与砷中毒。在甲基化过程中,三价甲基砷化合物可能以砷 - 谷胱甘肽共轭物的形式生成,例如二甲基亚砷酸谷胱甘肽(DMAs(III)G)。然而,关于DMAs(III)G的细胞毒性的信息较少。
我们使用高效薄层层析(HPTLC)方法合成并纯化了DMAs(III)G,并在大鼠肝细胞系(TRL 1215细胞)中测定了其细胞毒性。
DMAs(III)G在TRL 1215细胞中具有高度细胞毒性,半数致死浓度(LC(50))为160 nM。我们还发现,DMAs(III)G分子本身不能有效地转运到细胞内,也没有细胞毒性;然而,它很容易通过解离成三价二甲基砷化合物和谷胱甘肽(GSH)而变得具有强烈的细胞毒性。加入微摩尔生理浓度的GSH可防止DMAs(III)G的分解以及DMAs(III)G诱导的细胞毒性。生理浓度的正常人血清(HS)、人血清白蛋白(HSA)和人红细胞(HRBC)也降低了暴露于DMAs(III)G所诱导的细胞毒性和细胞砷摄取。
这些发现表明,即使DMAs(III)G在体内由As(III)形成,在健康人体中也可能看不到其显著的细胞毒性。